急性髓系白血病对过继性T细胞疗法反应的悖论
The Paradox of Acute Myeloid Leukemia Responsiveness to Adoptive T-cell Therapy.
作者信息
Fry Terry J
机构信息
Gates Institute; Pediatrics and Immunology, University of Colorado Anschutz Medical Campus, Aurora, Colorado.
出版信息
Blood Cancer Discov. 2025 May 5;6(3):157-158. doi: 10.1158/2643-3230.BCD-25-0017.
Abstract
Since the recognition of the allogeneic graft-versus-leukemia effect, acute myeloid leukemia (AML) has been identified as a T cell-targetable malignancy, but success with modern forms of immunotherapy has been slower than anticipated. In this issue, we discuss the biological barriers to the treatment of AML with T-cell therapy revealed by recent reports, including mechanistic insights into AML resistance to T cell-mediated killing by Tin and colleagues. See related article by Tin et al., p. 217.
摘要
自从认识到异基因移植物抗白血病效应以来，急性髓系白血病（AML）就被确定为一种可靶向T细胞的恶性肿瘤，但现代免疫疗法的成功进展比预期要慢。在本期中，我们讨论了近期报告所揭示的采用T细胞疗法治疗AML的生物学障碍，包括Tin及其同事对AML抵抗T细胞介导杀伤的机制性见解。见Tin等人的相关文章，第217页。
相似文献
1
The Paradox of Acute Myeloid Leukemia Responsiveness to Adoptive T-cell Therapy.急性髓系白血病对过继性T细胞疗法反应的悖论
Blood Cancer Discov. 2025 May 5;6(3):157-158. doi: 10.1158/2643-3230.BCD-25-0017.
2
A comprehensive analysis of primary acute myeloid leukemia identifies biomarkers predicting susceptibility to human allogeneic Vγ9Vδ2 T cells.一项对原发性急性髓系白血病的全面分析确定了预测人类同种异体Vγ9Vδ2 T细胞易感性的生物标志物。
J Immunother. 2014 Jul-Aug;37(6):321-30. doi: 10.1097/CJI.0000000000000043.
3
A modular and controllable T cell therapy platform for acute myeloid leukemia.用于急性髓系白血病的模块化和可控制的 T 细胞治疗平台。
Leukemia. 2021 Aug;35(8):2243-2257. doi: 10.1038/s41375-020-01109-w. Epub 2021 Jan 7.
4
CAR T-cell therapy in acute myeloid leukemia.嵌合抗原受体 T 细胞疗法治疗急性髓系白血病。
Saudi Med J. 2024 Oct;45(10):1007-1019. doi: 10.15537/smj.2024.45.10.20240330.
5
Generating and Expanding Autologous Chimeric Antigen Receptor T Cells from Patients with Acute Myeloid Leukemia.从急性髓系白血病患者中生成和扩增自体嵌合抗原受体T细胞。
Methods Mol Biol. 2017;1633:267-276. doi: 10.1007/978-1-4939-7142-8_17.
6
Prospects for immunotherapy of acute myeloid leukemia using γδ T cells.使用γδ T细胞进行急性髓系白血病免疫治疗的前景。
Immunotherapy. 2017 Jan;9(2):111-114. doi: 10.2217/imt-2016-0139.
7
Evolving strategies to overcome barriers in CAR-T cell therapy for acute myeloid leukemia.不断发展的策略以克服急性髓细胞白血病 CAR-T 细胞治疗中的障碍。
Expert Rev Hematol. 2024 Nov;17(11):797-818. doi: 10.1080/17474086.2024.2420614. Epub 2024 Oct 30.
8
Adoptive cell therapy in acute myeloid leukemia: the current landscape and emerging strategies.急性髓系白血病中的过继性细胞疗法：现状与新兴策略
Leuk Lymphoma. 2025 Feb;66(2):204-217. doi: 10.1080/10428194.2024.2414112. Epub 2024 Oct 25.
9
Adoptive cell therapy for acute myeloid leukemia.过继性细胞疗法治疗急性髓系白血病。
Leuk Lymphoma. 2019 Jun;60(6):1370-1380. doi: 10.1080/10428194.2018.1553300. Epub 2019 Jan 10.
10
Immunotherapy for acute myeloid leukemia (AML): a potent alternative therapy.免疫疗法治疗急性髓细胞白血病（AML）：一种强有力的替代疗法。
Biomed Pharmacother. 2018 Jan;97:225-232. doi: 10.1016/j.biopha.2017.10.100. Epub 2017 Nov 6.
本文引用的文献
1
SOCS1 Protects Acute Myeloid Leukemia against Allogeneic T Cell-Mediated Cytotoxicity.细胞因子信号转导抑制因子1保护急性髓系白血病免受同种异体T细胞介导的细胞毒性作用。
Blood Cancer Discov. 2025 May 5;6(3):217-232. doi: 10.1158/2643-3230.BCD-24-0140.
2
Honing CAR T cells to tackle acute myeloid leukemia.优化嵌合抗原受体T细胞以攻克急性髓系白血病。
Blood. 2025 Mar 13;145(11):1113-1125. doi: 10.1182/blood.2024024063.
3
Nanobody-based naturally selected CD7-targeted CAR-T therapy for acute myeloid leukemia.基于纳米抗体的自然选择靶向CD7的嵌合抗原受体T细胞疗法治疗急性髓系白血病
Blood. 2025 Mar 6;145(10):1022-1033. doi: 10.1182/blood.2024024861.
4
Cytokine-mediated CAR T therapy resistance in AML.细胞因子介导的急性髓系白血病中嵌合抗原受体T细胞疗法耐药性
Nat Med. 2024 Dec;30(12):3697-3708. doi: 10.1038/s41591-024-03271-5. Epub 2024 Sep 27.
5
AML/T cell interactomics uncover correlates of patient outcomes and the key role of ICAM1 in T cell killing of AML.AML/T 细胞相互作用组学揭示了与患者预后相关的因素，以及 ICAM1 在 T 细胞杀伤 AML 中的关键作用。
Leukemia. 2024 Jun;38(6):1246-1255. doi: 10.1038/s41375-024-02255-1. Epub 2024 May 9.
6
Comprehensive characterization of IFNγ signaling in acute myeloid leukemia reveals prognostic and therapeutic strategies.全面表征 IFNγ 信号在急性髓系白血病中的作用揭示了预后和治疗策略。
Nat Commun. 2024 Feb 28;15(1):1821. doi: 10.1038/s41467-024-45916-6.
7
Leukemia-intrinsic determinants of CAR-T response revealed by iterative in vivo genome-wide CRISPR screening.通过迭代体内全基因组 CRISPR 筛选揭示的 CAR-T 反应的白血病内在决定因素。
Nat Commun. 2023 Dec 5;14(1):8048. doi: 10.1038/s41467-023-43790-2.
8
Tumor-intrinsic sensitivity to the pro-apoptotic effects of IFN-γ is a major determinant of CD4 CAR T-cell antitumor activity.肿瘤内在对 IFN-γ 促凋亡作用的敏感性是 CD4 CAR T 细胞抗肿瘤活性的主要决定因素。
Nat Cancer. 2023 Jul;4(7):968-983. doi: 10.1038/s43018-023-00570-7. Epub 2023 May 29.
9
CAR T cell killing requires the IFNγR pathway in solid but not liquid tumours.CAR T 细胞杀伤需要 IFNγR 通路，但在实体瘤中而不是在液体肿瘤中。
Nature. 2022 Apr;604(7906):563-570. doi: 10.1038/s41586-022-04585-5. Epub 2022 Apr 13.
10
Blockade or Deletion of IFNγ Reduces Macrophage Activation without Compromising CAR T-cell Function in Hematologic Malignancies.阻断或缺失 IFNγ 可减少血液系统恶性肿瘤中巨噬细胞的活化而不影响 CAR T 细胞的功能。
Blood Cancer Discov. 2022 Mar 1;3(2):136-153. doi: 10.1158/2643-3230.BCD-21-0181.
Zotero 插件